Monitoring Skin Immune System (SIS) alterations in HS during treatment with biologics.

• Conditions: Verneuil's disease; 10040798; acne inversa

• Registration Number: NL-OMON49777
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

1. Age *18 years.
2. Indication for and starting with a biologic.
3. Able and willing to give written informed consent and to comply with the
study requirements.

Exclusion Criteria

1. Use of any medication potentially affecting the skin immune system or skin
microbiome.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the change in gene expression profile in lesional,<br /><br>peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic<br /><br>treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Microbial changes profile in lesional, peri-lesional an uninvolved skin in<br /><br>patients with HS after 12 weeks of biologic treatment.<br /><br>- Immunohistochemical changes profile in lesional, peri-lesional an uninvolved<br /><br>skin in patients with HS after 12 weeks of biologic treatment.<br /><br>- Change in protein expression profile in lesional, peri-lesional an<br /><br>uninvolved skin in patients with HS after 12 weeks of biologic treatment. </p><br>